Macro Dashboard
The macro regime remains split: Korea Bear, US Bull. The five-day KOSPI drawdown of −11.2% has triggered the bear confirmation, while US markets hold their uptrend. Korea’s breadth is weak — only 31% of KOSPI constituents trade above their 50-day average. On the US side, breadth is narrower than the index level implies (25.5% above 50-day), pointing to index-level concentration risk.
| Indicator | Level | 5-Day Change | Signal |
|---|---|---|---|
| KOSPI | 5,668.1 | −11.2% | Bear |
| KOSDAQ | 794.8 | −6.4% | Bear |
| VIX | 16.1 | +0.90 | Stable |
| US 10Y | 5.09% | −0.15pp | Easing |
| USD/KRW | 1,331 | −10.0 won | Won firming |
| Brent | $106.2 | −0.4% | Flat |
KR regime: Bear — US regime: Bull. Rule-based stance: reduce KR exposure, hold US.
Market Wrap
Source: KR Market Snapshot (2026-10-16). Same-day full close briefing was unavailable; this section draws on the Research OS DB snapshot.
Today’s session was a broad-based rebound within an ongoing bear trend. Of 2,593 stocks tracked, 2,011 advanced and only 374 declined — an advance-decline ratio of roughly 5.4-to-1. The average stock moved +2.46%, suggesting the bounce was not confined to large-caps.
The backdrop matters: this rally follows a five-day KOSPI decline of more than 11%. Today’s session looks like short-covering and opportunistic buying rather than a regime shift. Breadth above 50-day moving averages remains weak at 31%, so individual sessions of strength should be evaluated against that structural overhang.
Flow picture was mixed but constructive on select themes. Foreign investors net-bought Hyundai Motor (005380.KS, +5.58%), Samsung C&T (028260.KS, +7.10%), NAVER (035420.KS, +3.69%), KB Financial (105560.KS, +2.11%), and LG CNS (064400.KS, +5.16%). The auto/mobility complex and domestic consumption leaders attracted foreign interest. APR (278470.KS, +9.23%) also saw foreign net buying — the beauty/K-culture theme continues to attract offshore capital despite the broad market selloff.
On the institutional side, Samsung Biologics (207940.KS, +4.09%), Samyang Foods (003230.KS, +6.78%), HYBE (352820.KS, +7.09%), and Hyundai Glovis (086280.KS, +5.53%) topped institutional net buy lists. The divergence at Samsung Biologics is notable: foreigners sold, institutions bought — a tug-of-war worth monitoring ahead of any upcoming earnings or pipeline update.
Weak spots: L&F (066970.KS, −10.51%) was sold by both foreigners and institutions — the battery materials theme continues to face pressure. S-Oil (010950.KS, −3.58%) and Samsung SDI (006400.KS, −1.85%) also underperformed. Derivatives data shows OI declined by nearly 14,000 contracts and ETF net creation was negative at −₩334.9bn, suggesting net passive outflow even as spot prices bounced.
Session character: Bear-market bounce with selective leadership in autos, bio/pharma, and content. Battery materials and refining lagged. The real test is whether institutional buying in large-cap bio and auto can hold into next week.
Today’s Quality Re-Rating Candidates
Source: KR Meta Screener (2026-10-16). PEAD screener data is from 2026-10-09 and is treated as a supplemental reference — no same-day PEAD overlap exists. The intersection table shows zero two-screener overlaps from the standalone overlap engine, so meta screener rank takes priority.
The meta screener scanned 83 tickers and scored each across up to six independent evidence families: fundamental quality, earnings/cycle, investor flow, market activity, price leadership, and official DART catalysts. Names scoring across five or more independent families are the strongest research candidates.
Top Candidates Table
| Rank | Ticker | Name | Meta Score | Evidence Families | Screeners Hit | Key Metrics |
|---|---|---|---|---|---|---|
| 1 | 068270.KS | Celltrion | 64.6 | 6 | Cycle Rerating, Smart Money Quality, Smart Money Earnings, RS80, Kiwoom Surface | Margin +14.2pp, F+QI flow +₩144.2bn (5D) |
| 2 | 096530.KQ | Seegene | 52.0 | 5 | Quality Compounder, Cycle Rerating, Smart Money Quality, Smart Money Earnings, Kiwoom Surface | ROE 4.8%, OP YoY +309.7%, margin +11.3pp |
| 3 | 204620.KQ | Global Tax Free | 49.7 | 5 | Quality Compounder, RS80, Kiwoom Surface | ROE 27.8%, OP YoY +34.3%, pivot gap +9.3% |
| 4 | 098120.KQ | Microcontact Sol | 49.2 | 5 | Quality Compounder, Cycle Rerating, Kiwoom Surface | ROE 23.1%, OP YoY +73.5%, margin +3.0pp |
| 5 | 011200.KS | HMM | 46.8 | 6 | Smart Money Quality, Consensus Up, RS80, Kiwoom Surface | F+QI flow +₩117.4bn (5D), consensus z +0.33 |
| 6 | 003350.KS | Korea Cosmetics Mfg | 39.8 | 4 | Quality Compounder, Cycle Rerating, Kiwoom Surface | ROE 30.6%, OP YoY +24.2% — 3 DART risk filings |
| 7 | 033780.KS | KT&G | 38.7 | 3 | Quality Compounder, RS80, Kiwoom Surface | ROE 11.7%, OP YoY +13.0%, foreign ownership 51% |
| 8 | 089860.KS | Lotte Rental | 37.3 | 5 | Cycle Rerating, RS80, Kiwoom Surface | Margin +0.5pp, foreign net buy confirmed |
| 9 | 021240.KS | Coway | 37.1 | 4 | Quality Compounder, RS80, Kiwoom Surface | ROE 17.1%, OP YoY +10.5% — short ratio 18.4% caution |
| 10 | 003380.KS | Harim Holdings | 36.9 | 5 | Cycle Rerating, RS80, Kiwoom Surface | 2 DART catalysts, F+QI absorbing retail selling |
Deep Dive: Top 3 Names
1. Celltrion (068270.KS) — Score 64.6, 6 evidence families
Celltrion is Korea’s leading biosimilar manufacturer, with commercial products covering oncology, autoimmune, and infectious disease indications. It is the only name today reaching six independent evidence families. The key signal is a margin expansion of +14.2 percentage points in the most recent reporting period, combined with ₩144.2bn in net foreign-plus-institutional buying over the past five days — while retail investors sold ₩226bn into that demand. When smart money absorbs aggressive retail distribution at this scale, it warrants scrutiny. Three recent DART filings strengthen the case: a Phase 3 IND approval for CT-P13 SC (Zymfentra, subcutaneous formulation) in Korea (Oct 14), a preliminary earnings disclosure (Oct 12), and a share buyback resolution (Sep 29). The earnings disclosure is the key event to verify — if operating leverage is confirmed at the scale the screener flags, the re-rating thesis becomes more defensible. Next check: confirm the preliminary earnings figures against DART XBRL data and monitor whether the institutional/foreign bid persists post-results.
2. Seegene (096530.KQ) — Score 52.0, 5 evidence families
Seegene is a molecular diagnostics company specializing in multiplex PCR kits. After pandemic-era distortions, the company is showing genuine earnings recovery: OP YoY +309.7% on a low base, with operating margin expanding +11.3pp. The quality screener (Quality Compounder) passes it on ROE of 4.8% — modest but positive after a trough year. The cycle re-rating flag here reflects margin normalization rather than a cyclical commodity call. Smart money quality and earnings screeners both fire: ₩9.5bn in net institutional/foreign buying over five days with retail selling on the other side. The DART filing is a Q3 interim dividend record date (Sep 28) — routine, but signals management confidence. Caution: short ratio is 7.7%, program buying is +11.1%, and the stock sits at institutional rank #310 on the Kiwoom surface — the short position is worth monitoring. Next check: verify whether the earnings recovery trajectory extends into H2 2026 and whether the dividend signals a structural payout policy shift.
3. HMM (011200.KS) — Score 46.8, 6 evidence families
HMM is Korea’s largest container shipping operator. It scores six evidence families despite missing the Quality Compounder gate (not in that screener), compensating with smart money flow, consensus revision, RS80 leadership, and DART filings. The five-day foreign-plus-institutional net inflow of ₩117.4bn — against ₩180.8bn in retail selling — is one of the largest absorption figures in today’s screener. Consensus estimates have been revised upward (composite z-score +0.33). Three DART filings from October 15 cover a shareholder meeting convening, a record date, and a new capex decision — the capex filing is the item to read carefully for fleet expansion or drydock implications. The RS80 not-late signal shows a pivot gap of +3.7% with a 20-day flow score of +21.97%, suggesting institutional accumulation is still in early stages rather than exhausted. The primary risk is freight rate volatility — any deterioration in trans-Pacific or Asia-Europe rates would pressure the re-rating thesis quickly. Next check: read the DART capex filing and cross-reference with spot container rate indices before treating the consensus revision as durable.
All screener data as of 2026-10-16. PEAD screener data referenced from 2026-10-09 (most recent available). This post is market analysis only — it does not constitute investment advice. All metrics should be independently verified against current filings and real-time price data.